MET Stock Cash Flow Statements

MetLife Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

MetLife Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-09-30	2024-06-30	2024-03-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31

net cash from operating activities	2,187,000,000	4,262,000,000	4,169,000,000	3,490,000,000	2,328,000,000	3,475,000,000	3,038,000,000	2,026,000,000	2,534,000,000	4,278,000,000	4,438,000,000	1,954,000,000	3,506,000,000	2,254,000,000	1,496,000,000	5,153,000,000	3,793,000,000	846,000,000	1,847,000,000	4,146,000,000	2,387,000,000	2,072,000,000	3,533,000,000	5,608,000,000	1,296,000,000	4,734,000,000	3,401,000,000	2,098,000,000	2,928,000,000	4,291,000,000	1,964,000,000	2,639,000,000	4,202,000,000	2,686,000,000	4,029,000,000	4,437,000,000	2,484,000,000	2,670,000,000	4,581,000,000	2,733,000,000
cash flows from investing activities
sales, maturities and repayments of:
fixed maturity securities available-for-sale	13,441,000,000	14,062,000,000	14,515,000,000	15,371,000,000	11,469,000,000	13,097,000,000	13,678,000,000	18,737,000,000	22,557,000,000	18,365,000,000	28,278,000,000	19,737,000,000	19,579,000,000	19,223,000,000	24,976,000,000	21,107,000,000	16,838,000,000	20,656,000,000	19,378,000,000	14,969,000,000	20,449,000,000	21,606,000,000
equity securities	45,000,000	9,000,000	45,000,000	7,000,000	37,000,000	80,000,000	866,000,000	61,000,000	252,000,000	148,000,000	89,000,000	384,000,000	141,000,000	179,000,000	156,000,000	105,000,000	137,000,000	100,000,000	25,000,000	37,000,000	34,000,000	149,000,000	43,000,000	93,000,000	187,000,000	452,000,000	264,000,000	188,000,000	126,000,000	262,000,000	631,000,000	294,000,000	126,000,000	58,000,000	135,000,000	248,000,000	72,000,000	118,000,000	200,000,000	249,000,000
mortgage loans	3,187,000,000	3,234,000,000	2,426,000,000	2,560,000,000	2,217,000,000	2,224,000,000	3,002,000,000	1,345,000,000	1,796,000,000	2,298,000,000	3,281,000,000	3,404,000,000	4,066,000,000	4,963,000,000	3,663,000,000	3,452,000,000	2,791,000,000	2,236,000,000	2,821,000,000	2,870,000,000	3,296,000,000	1,769,000,000	2,537,000,000	2,265,000,000	2,076,000,000	2,367,000,000	2,578,000,000	1,776,000,000	3,767,000,000	3,894,000,000	2,857,000,000	3,281,000,000	3,775,000,000	2,719,000,000	4,360,000,000	3,584,000,000	2,973,000,000	2,967,000,000	2,523,000,000	2,510,000,000
real estate and real estate joint ventures	24,000,000	48,000,000	264,000,000	155,000,000	143,000,000	47,000,000	50,000,000	26,000,000	630,000,000	28,000,000	355,000,000	83,000,000	424,000,000	630,000,000	106,000,000	10,000,000	7,000,000	13,000,000	90,000,000	414,000,000	35,000,000	103,000,000	139,000,000	294,000,000	128,000,000	199,000,000	451,000,000	39,000,000	152,000,000	115,000,000	56,000,000	1,141,000,000	223,000,000	280,000,000	147,000,000	125,000,000	260,000,000	52,000,000	185,000,000	86,000,000
other limited partnership interests	203,000,000	301,000,000	216,000,000	224,000,000	402,000,000	157,000,000	247,000,000	294,000,000	309,000,000	79,000,000	326,000,000	901,000,000	180,000,000	158,000,000	174,000,000	292,000,000	145,000,000	14,000,000	146,000,000	146,000,000	152,000,000	250,000,000	177,000,000	198,000,000	139,000,000	193,000,000	228,000,000	461,000,000	575,000,000	155,000,000	295,000,000	277,000,000	303,000,000	279,000,000	172,000,000	163,000,000	220,000,000	36,000,000	285,000,000	225,000,000
short-term investments	3,296,000,000	4,143,000,000	2,102,000,000	3,888,000,000	3,753,000,000	4,418,000,000	2,814,000,000	3,448,000,000
purchases and originations of:
cash received in connection with freestanding derivatives	635,000,000	803,000,000	691,000,000	531,000,000	503,000,000	514,000,000	246,000,000	1,200,000,000	1,349,000,000	662,000,000	1,421,000,000	1,092,000,000	805,000,000	411,000,000	1,358,000,000	-276,000,000	-133,000,000	269,000,000	4,987,000,000	1,253,000,000	703,000,000	1,021,000,000	754,000,000	402,000,000	1,974,000,000	945,000,000	1,430,000,000	2,515,000,000	780,000,000	1,141,000,000	1,337,000,000	852,000,000	577,000,000	947,000,000	274,000,000	308,000,000	395,000,000	556,000,000	447,000,000	330,000,000
cash paid in connection with freestanding derivatives	-946,000,000	-1,013,000,000	-522,000,000	-1,209,000,000	-1,052,000,000	-1,474,000,000	-1,196,000,000	-1,546,000,000	-1,725,000,000	-1,550,000,000	-2,604,000,000	-1,914,000,000	-1,192,000,000	-814,000,000	-4,788,000,000	-1,347,000,000	-883,000,000	-577,000,000	-1,440,000,000	-832,000,000	-1,231,000,000	-1,231,000,000	-1,107,000,000	-446,000,000	-2,192,000,000	-1,706,000,000	-2,326,000,000	-3,372,000,000	-1,608,000,000	-1,536,000,000	-1,173,000,000	-287,000,000	-1,106,000,000	-1,494,000,000	-527,000,000	-958,000,000	-1,045,000,000	-1,293,000,000	-1,872,000,000	-2,428,000,000
net change in policy loans	57,000,000	-87,000,000	-42,000,000	63,000,000	-80,000,000	26,000,000	20,000,000	-4,000,000	16,000,000	9,000,000	44,000,000	35,000,000	42,000,000	52,000,000	85,000,000	144,000,000	94,000,000	-8,000,000	20,000,000	10,000,000	-20,000,000	16,000,000	-20,000,000	-17,000,000	-25,000,000	-22,000,000	26,000,000	-20,000,000	94,000,000	22,000,000	85,000,000	15,000,000	2,000,000	-7,000,000	-14,000,000	-3,000,000	-2,000,000	18,000,000	-59,000,000	-52,000,000
net change in other invested assets	100,000,000	457,000,000	49,000,000	-226,000,000	-280,000,000	56,000,000	-890,000,000	-243,000,000	38,000,000	-87,000,000	-514,000,000	-223,000,000	-307,000,000	63,000,000	-23,000,000	-121,000,000	-120,000,000	66,000,000	-1,000,000	-306,000,000	118,000,000	-53,000,000	10,000,000	118,000,000	46,000,000	22,000,000	-163,000,000	-43,000,000	-191,000,000	-119,000,000	252,000,000	-93,000,000	-90,000,000	-167,000,000	-31,000,000	-335,000,000	115,000,000	53,000,000	52,000,000	-226,000,000
other	-23,000,000	-51,000,000	-57,000,000	-113,000,000	-14,000,000	-18,000,000	-10,000,000	-97,000,000	274,000,000	5,000,000	-115,000,000	81,000,000	-36,000,000	-23,000,000	17,000,000	215,000,000	-29,000,000	240,000,000	-75,000,000	-37,000,000	-37,000,000	-55,000,000	12,000,000	-74,000,000	86,000,000	-62,000,000	-96,000,000	-98,000,000	-139,000,000	-222,000,000	-23,000,000	-41,000,000	-64,000,000	-86,000,000	-21,000,000	-44,000,000	-66,000,000	-40,000,000	-18,000,000	40,000,000
net cash from investing activities	-2,981,000,000	-3,322,000,000	-2,162,000,000	-1,340,000,000	-2,627,000,000	-2,972,000,000	-6,346,000,000	-1,504,000,000	-197,000,000	-4,112,000,000	2,115,000,000	-426,000,000	-8,280,000,000	1,009,000,000	-1,054,000,000	-2,162,000,000	-6,679,000,000	-1,391,000,000	-8,337,000,000	-5,351,000,000	557,000,000	-5,699,000,000	-6,228,000,000	-4,279,000,000	-485,000,000	-10,009,000,000	-2,873,000,000	-4,276,000,000	-4,678,000,000	-4,169,000,000	-5,739,000,000	-147,000,000	140,000,000	-6,900,000,000	-4,969,000,000	-8,864,000,000	2,164,000,000	1,278,000,000	1,866,000,000	-9,719,000,000
cash flows from financing activities
policyholder account balances - deposits	27,064,000,000	28,692,000,000	24,858,000,000	25,567,000,000	24,444,000,000	22,458,000,000
policyholder account balances - withdrawals	-24,753,000,000	-26,916,000,000	-24,269,000,000	-24,692,000,000	-23,373,000,000	-21,821,000,000
net change in payables for collateral under securities loaned and other transactions	-351,000,000	233,000,000	-779,000,000	335,000,000	50,000,000	-955,000,000	-906,000,000	-1,066,000,000	-4,128,000,000	1,207,000,000	-6,478,000,000	-1,331,000,000	773,000,000	1,932,000,000	-1,426,000,000	-4,487,000,000	624,000,000	-1,395,000,000	8,796,000,000	2,978,000,000	337,000,000	388,000,000	-914,000,000	966,000,000	667,000,000	1,111,000,000	814,000,000	391,000,000	-1,367,000,000	4,433,000,000	4,161,000,000	2,459,000,000	-1,780,000,000	1,985,000,000	590,000,000	833,000,000	2,058,000,000	-1,381,000,000	-968,000,000	528,000,000
long-term debt issued	624,000,000	89,000,000	277,000,000	512,000,000	758,000,000	1,003,000,000	0	1,000,000,000	0	1,007,000,000			14,000,000			0	50,000,000	0	1,074,000,000	0			10,000,000	0	14,000,000	668,000,000						86,000,000	0	1,492,000,000	0
long-term debt repaid	-3,000,000	-555,000,000	-1,000,000	-1,477,000,000	-264,000,000	-8,000,000	-7,000,000	-1,012,000,000	-8,000,000	-54,000,000	-13,000,000	-10,000,000	-512,000,000	-13,000,000	-15,000,000	-4,000,000	-82,000,000	-7,000,000	-6,000,000	-6,000,000	-885,000,000	-10,000,000	-1,111,000,000	-168,000,000	-32,000,000	-51,000,000	-5,000,000	-4,000,000	-9,000,000	-1,259,000,000	-5,000,000	-58,000,000	-1,013,000,000	-7,000,000	-318,000,000	-1,024,000,000	-1,460,000,000	-409,000,000	-116,000,000	-240,000,000
collateral financing arrangement repaid	-25,000,000	-13,000,000	-26,000,000	-35,000,000	-47,000,000	-24,000,000	-29,000,000	-12,000,000	-13,000,000	-12,000,000	-13,000,000	-12,000,000	-12,000,000	-15,000,000	-12,000,000	-79,000,000	-44,000,000	-13,000,000	-12,000,000	-13,000,000
subordinated debt securities issued	0	1,000,000,000
derivatives with certain financing elements and other derivative-related transactions	-3,000,000	-71,000,000	109,000,000	-95,000,000	-55,000,000
proceeds from mortgage loan secured financing	268,000,000	66,000,000	55,000,000	50,000,000	42,000,000	63,000,000
repayments of mortgage loan secured financing	-417,000,000	-255,000,000	-159,000,000	-258,000,000	-161,000,000	-62,000,000
treasury stock acquired in connection with share repurchases	-510,000,000	-1,411,000,000	-774,000,000	-855,000,000	-1,172,000,000	-792,000,000	-672,000,000	-780,000,000	-596,000,000	-674,000,000	-1,116,000,000	-940,000,000	-1,015,000,000	-1,113,000,000	-999,000,000	-571,000,000	-80,000,000	0	-500,000,000	-785,000,000	-750,000,000	-500,000,000	-636,000,000	-1,115,000,000	-1,041,000,000	-495,000,000	-952,000,000	-858,000,000	0	0	-70,000,000	-107,000,000	-14,000,000	-986,000,000	-439,000,000
dividends on preferred stock	-31,000,000	-66,000,000	-67,000,000	-34,000,000	-67,000,000	-67,000,000	-32,000,000	-66,000,000	-29,000,000	-64,000,000	-29,000,000	-63,000,000	-63,000,000	-35,000,000	-68,000,000	-34,000,000	-59,000,000	-77,000,000	-32,000,000	-32,000,000	-57,000,000	-32,000,000	-32,000,000	-46,000,000	-6,000,000	-6,000,000	-46,000,000	-6,000,000	-6,000,000	-46,000,000	-6,000,000	-6,000,000	-31,000,000	-30,000,000	-30,000,000	-31,000,000	-30,000,000	-30,000,000	-31,000,000	-30,000,000
dividends on common stock	-382,000,000	-374,000,000	-383,000,000	-389,000,000	-377,000,000	-392,000,000	-399,000,000	-389,000,000	-393,000,000	-400,000,000	-408,000,000	-397,000,000	-413,000,000	-421,000,000	-408,000,000	-415,000,000	-419,000,000	-419,000,000	-404,000,000	-413,000,000	-419,000,000	-405,000,000	-419,000,000	-428,000,000	-416,000,000	-427,000,000	-431,000,000	-437,000,000	-441,000,000	-441,000,000	-413,000,000	-420,000,000	-420,000,000	-394,000,000	-395,000,000	-395,000,000	-311,000,000	-303,000,000	-302,000,000	-203,000,000
net cash from financing activities	1,449,000,000	220,000,000	-1,146,000,000	-1,205,000,000	-261,000,000	-848,000,000	379,000,000	-2,295,000,000	-4,701,000,000	1,775,000,000	-9,133,000,000	1,951,000,000	-1,108,000,000	1,632,000,000	-564,000,000	-6,993,000,000	2,885,000,000	680,000,000	14,157,000,000	2,327,000,000	934,000,000	2,316,000,000	-1,081,000,000	1,394,000,000	218,000,000	883,000,000	-693,000,000	1,499,000,000	612,000,000	3,376,000,000	4,240,000,000	-288,000,000	-4,287,000,000	1,723,000,000	2,411,000,000	3,225,000,000	-3,659,000,000	-1,794,000,000	-7,114,000,000	1,324,000,000
effect of change in foreign currency exchange rates on cash and cash equivalents balances	197,000,000	98,000,000	118,000,000	1,000,000	-239,000,000	-160,000,000	-110,000,000	34,000,000	359,000,000	-289,000,000	-383,000,000	-84,000,000	-200,000,000	0	-192,000,000	157,000,000	117,000,000	60,000,000	-171,000,000	-105,000,000	51,000,000	-4,000,000	-46,000,000	-338,000,000	197,000,000	96,000,000	73,000,000	213,000,000	-46,000,000	279,000,000	73,000,000	-62,000,000	-108,000,000	-190,000,000	-81,000,000	22,000,000	-1,000,000	38,000,000	-132,000,000	-93,000,000
change in cash and cash equivalents	852,000,000	1,258,000,000	979,000,000	946,000,000	-799,000,000	-505,000,000	-3,039,000,000	-1,739,000,000	-2,005,000,000	1,652,000,000	-2,963,000,000	3,395,000,000	-6,082,000,000	4,895,000,000	-314,000,000	-3,845,000,000	116,000,000	195,000,000	7,496,000,000	1,017,000,000	3,929,000,000	-1,315,000,000	-3,822,000,000	2,385,000,000	1,226,000,000	-4,296,000,000	-92,000,000	-466,000,000	-1,184,000,000	3,777,000,000	538,000,000	2,142,000,000	-53,000,000	-2,681,000,000	1,390,000,000	-1,180,000,000	988,000,000	2,192,000,000	-799,000,000	-5,755,000,000
cash and cash equivalents, beginning of period	0	20,068,000,000	0	0	20,639,000,000	0	0	20,195,000,000		0	0	20,047,000,000	0	0	19,795,000,000		0	0	16,598,000,000	0	0	15,821,000,000	0	0	12,701,000,000	0	0	17,877,000,000	0	0	12,752,000,000	0	0	10,808,000,000	0	0	7,585,000,000	0	0	15,738,000,000
cash and cash equivalents, end of period	852,000,000	21,326,000,000	979,000,000	946,000,000	19,840,000,000	-505,000,000	-3,039,000,000	18,456,000,000		1,652,000,000	-2,940,000,000	23,488,000,000	-6,081,000,000	5,402,000,000	19,635,000,000		116,000,000	195,000,000	24,094,000,000	1,017,000,000	3,929,000,000	14,506,000,000	-3,822,000,000	2,385,000,000	13,927,000,000	-4,296,000,000	-92,000,000	17,411,000,000	-1,184,000,000	3,777,000,000	13,290,000,000	2,142,000,000	-53,000,000	8,127,000,000	1,390,000,000	-1,180,000,000	8,573,000,000	2,192,000,000	-799,000,000	9,983,000,000
sales of businesses, net of cash and cash equivalents disposed of 0 and 67, respectively
purchases of investments in operating joint ventures									0	0	0	-240,000,000																	0
financing element on certain derivative instruments and other derivative related transactions						-228,000,000	-2,000,000	60,000,000			16,000,000	105,000,000	-13,000,000	-8,000,000	326,000,000	62,000,000	134,000,000	-75,000,000	-167,000,000	32,000,000	15,000,000	-29,000,000	-27,000,000	-25,000,000	37,000,000	-15,000,000	-282,000,000	188,000,000
cash and cash equivalents, including subsidiaries held-for-sale, beginning of period						0	0	20,195,000,000		0	0	20,116,000,000
cash and cash equivalents, including subsidiaries held-for-sale, end of period						-505,000,000	-3,039,000,000	18,456,000,000		1,652,000,000	-2,963,000,000	23,511,000,000
cash and cash equivalents, subsidiaries held-for-sale, beginning of period										0	0	69,000,000
cash and cash equivalents, subsidiaries held-for-sale, end of period												23,000,000
policyholder account balances:
deposits								26,963,000,000	19,329,000,000	27,598,000,000	27,774,000,000	28,335,000,000	24,671,000,000	25,143,000,000	25,722,000,000	19,871,000,000	23,506,000,000	25,300,000,000	24,820,000,000	24,134,000,000	21,620,000,000	23,891,000,000	25,179,000,000	21,997,000,000	24,861,000,000	22,711,000,000	23,583,000,000	21,271,000,000	23,877,000,000	21,423,000,000	19,925,000,000	24,950,000,000	21,970,000,000	22,463,000,000	27,008,000,000	27,843,000,000	19,004,000,000	18,661,000,000	20,137,000,000	21,370,000,000
withdrawals								-26,885,000,000	-18,772,000,000	-26,686,000,000	-28,775,000,000	-23,653,000,000	-24,500,000,000	-23,468,000,000	-23,527,000,000	-20,395,000,000	-21,747,000,000	-22,632,000,000	-20,477,000,000	-23,710,000,000	-20,041,000,000	-20,904,000,000	-22,893,000,000	-20,529,000,000	-24,447,000,000	-19,846,000,000	-23,287,000,000	-19,100,000,000	-21,252,000,000	-20,583,000,000	-19,310,000,000	-26,568,000,000	-23,636,000,000	-22,736,000,000	-23,680,000,000	-24,993,000,000	-22,628,000,000	-19,289,000,000	-25,818,000,000	-20,034,000,000
cash flows from operating activities
net income
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization expenses
amortization of premiums and accretion of discounts associated with investments
(gains) losses on investments and from sales of businesses
(gains) losses on derivatives
(income) income from equity method investments, net of dividends or distributions
interest credited to policyholder account balances
universal life and investment-type product policy fees
change in contractholder-directed equity securities and fair value option securities
change in accrued investment income
change in premiums, reinsurance and other receivables
change in deferred policy acquisition costs and value of business acquired
change in income tax
change in other assets
change in insurance-related liabilities and policy-related balances
change in other liabilities
sales of businesses, net of cash and cash equivalents disposed of 67, 611 and 0, respectively
purchases of businesses, net of cash received of 4, 0 and 191, respectively
payables for collateral under securities loaned and other transactions:
cash received for other transactions with tenors greater than three months																0	100,000,000	0	50,000,000
cash paid for other transactions with tenors greater than three months													0	0	-100,000,000	0	-125,000,000	0	-50,000,000	0	-125,000,000	-75,000,000
preferred stock issued, net of issuance costs																0	989,000,000	0	972,000,000				0	780,000,000	494,000,000							-2,000,000
redemption of preferred stock													0
preferred stock redemption premium													0
cash and cash equivalents, including subsidiaries held-for-sale, beginning of year
cash and cash equivalents, including subsidiaries held-for-sale, end of year
cash and cash equivalents, subsidiaries held-for-sale, beginning of year
cash and cash equivalents, subsidiaries held-for-sale, end of year
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
supplemental disclosures of cash flow information
net cash paid (received) for:
interest																		290,000,000	136,000,000	137,000,000	362,000,000	148,000,000	217,000,000				319,000,000	255,000,000	252,000,000	374,000,000	249,000,000	249,000,000	373,000,000	214,000,000	218,000,000	378,000,000	245,000,000	273,000,000	354,000,000	264,000,000
income tax																		165,000,000	-35,000,000	86,000,000	642,000,000	114,000,000	118,000,000				396,000,000	109,000,000	71,000,000	268,000,000	125,000,000	560,000,000	197,000,000	147,000,000	81,000,000	235,000,000	97,000,000	95,000,000	227,000,000	217,000,000
business acquisitions
assets
liabilities
cash paid, excluding transaction costs
non-cash transactions:
fixed maturity securities available-for-sale received in connection with pension risk transfer transactions																				0
real estate and real estate joint ventures acquired in satisfaction of debt																																						0	0	55,000,000
increase in equity securities due to in-kind distributions received from other limited partnership interests
reclassification of certain other invested assets to contractholder-directed equity securities and fair value option securities
sales of businesses, net of cash and cash equivalents disposed of 67 and 611, respectively										0
net change in short-term investments										-2,387,000,000	233,000,000	3,986,000,000	-3,281,000,000	944,000,000	-828,000,000	-306,000,000	1,537,000,000	553,000,000	-2,125,000,000	-721,000,000	1,747,000,000	-545,000,000	-1,356,000,000	1,215,000,000	-160,000,000	-1,123,000,000	2,806,000,000	-1,892,000,000	-1,817,000,000	1,887,000,000	-2,302,000,000	-411,000,000	-543,000,000	-5,690,000,000	122,000,000	1,327,000,000	47,000,000	392,000,000	577,000,000	3,303,000,000
sales of businesses, net of cash and cash equivalents disposed of 611 and 0, respectively													0
cash and cash equivalents, including subsidiary held-for-sale, beginning of period													0	0	20,560,000,000
cash and cash equivalents, including subsidiary held-for-sale, end of period													-6,082,000,000	4,895,000,000	20,246,000,000
cash and cash equivalents, subsidiary held-for-sale, beginning of period													0	0	765,000,000
cash and cash equivalents, subsidiary held-for-sale, end of period													-1,000,000	-507,000,000	611,000,000
purchases of businesses, net of cash received of 191, 0 and 0, respectively
cash and cash equivalents, including subsidiary held-for-sale, end of year
cash and cash equivalents, subsidiary held-for-sale, end of year
subsidiary held-for-sale
assets held-for-sale
liabilities held-for-sale
net assets held-for-sale
operating lease liability associated with the recognition of right-of-use assets
brighthouse common stock exchange transaction
reduction of long-term debt																							0												0	0	413,000,000
reduction of fair value option securities																							0
reclassification of certain equity securities to other invested assets
increase in policyholder account balances associated with funding agreement backed notes issued but not settled
brighthouse common stock exchange transaction:
collateral financing arrangements repaid																						-12,000,000	-12,000,000	-23,000,000	-13,000,000	-16,000,000	-2,824,000,000	-12,000,000	-29,000,000	-14,000,000	-12,000,000	-12,000,000
purchases of:
cash disposed due to distribution of brighthouse
purchases of businesses
distribution of brighthouse
cash and cash equivalents, of disposed subsidiary, beginning of period
cash and cash equivalents, of disposed subsidiary, end of period
cash and cash equivalents, from continuing operations, beginning of period																							0	0	12,701,000,000
cash and cash equivalents, from continuing operations, end of period																							-3,822,000,000	2,385,000,000	13,927,000,000
fixed maturity securities available-for-sale received in connection with pension risk transfer transaction
disposal of brighthouse
assets disposed
liabilities disposed
net assets disposed
cash disposed
net non-cash disposed
fixed maturity securities																								28,444,000,000	26,053,000,000	19,424,000,000	24,034,000,000	23,086,000,000	34,109,000,000	32,410,000,000	35,095,000,000	31,443,000,000	42,218,000,000	35,647,000,000	28,393,000,000	28,890,000,000	27,904,000,000	31,298,000,000	34,650,000,000	30,024,000,000
fixed maturity securities received in connection with pension risk transfer transaction
sales of businesses, net of cash and cash equivalents disposed of 0 and 135, respectively
reduction of fixed maturity securities in connection with a reinsurance transaction																													0	0	224,000,000
deconsolidation of operating joint venture:
reduction of fixed maturity securities																													0	0	917,000,000
reduction of noncontrolling interests																													0	0	373,000,000
net change in short-term debt																												18,000,000	-6,000,000						0	0	-75,000,000
cash received under repurchase agreements																																0	0	199,000,000
cash paid under reverse repurchase agreements																																0	0	-199,000,000
sales of businesses, net of cash and cash equivalents disposed of 135 and 0, respectively
repurchase of preferred stock																																-555,000,000
preferred stock repurchase premium																																-15,000,000
fixed maturity securities received in connection with pension risk transfer transactions
deconsolidation of operating joint venture
sales of businesses, net of cash and cash equivalents disposed of 0 and 262, respectively
purchases of investments in insurance joint ventures																																			-28,000,000
cash received (paid) in connection with collateral financing arrangements
fixed maturity securities received in connection with pension closeout transactions
deconsolidation of metlife core property fund:
reduction of redeemable noncontrolling interests																																			0	0	774,000,000
reduction of real estate and real estate joint ventures																																			0	0	1,132,000,000
sales of businesses, net of cash and cash equivalents disposed of 262 and 13, respectively
sale of bank deposits																																						0	0	-6,395,000,000
net change in bank deposits																																						0	0	8,000,000
common stock issued, net of issuance costs
deconsolidation of metlife core property fund
sales of businesses, net of cash and cash equivalents disposed of 262 and 0, respectively
dividends on common stock declared and unpaid
sales of businesses																																							0	373,000,000
supplemental disclosures of cash flow information:
net change in securitized reverse residential mortgage loans
sales of businesses, net of cash and cash equivalents disposed of 13 and 0, respectively
net change in liability for securitized reverse residential mortgage loans
redemption of advances agreements in long-term debt
issuance of funding agreements in policyholder account balances
sale of interest in joint venture
cash received in connection with collateral financing arrangements
cash paid in connection with collateral financing arrangements
debt issuance costs
stock options exercised
redemption of convertible preferred stock
net cash paid during the period for:
non-cash transactions during the period:

We provide you with 20 years of cash flow statements for MetLife stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MetLife stock. Explore the full financial landscape of MetLife stock with our expertly curated income statements.

The information provided in this report about MetLife stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.